Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-2173 in Primary Immune Thrombocytopenia
NCT07206758Phase 1Recruiting
- Sponsor
- Hengrui Therapeutics
- Start
- Nov 2025
- Primary completion
- Jun 2026
- Modality
- Biological product
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SHR-2173 in immune thrombocytopenia (ITP), sponsored by Hengrui Therapeutics. Primary endpoints: Incidence of adverse events (AE) and serious adverse events (SAE) and adverse events of special concern (AESI) at 9 months, Severity of adverse events (AE) and serious adverse events (SAE) and adverse events of special concern (AESI) at 9 months and 1 more. Started Nov 2025; status: recruiting.
02
Drugs
SHR-2173
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT07206758.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07206758.